title: Seroprevalence of Antibodies to Pertussis Toxin among Different Age Groups in Thailand after 37 Years of Universal Whole-Cell Pertussis Vaccination.
abstract: Despite the high coverage of prophylactic vaccine against Bordetella pertussis infection in many countries for more than three decades, pertussis remains a common vaccine-preventable disease. Infections have been detected more commonly in countries using acellular pertussis vaccine in their Expanded Program of Immunization. Thailand implemented a routine infant immunization program with whole-cell pertussis vaccine in 1977, and since 1992, the national vaccine policy has offered a five-dose whole-cell pertussis vaccine for children given at the ages of 2, 4, 6, 18, and 48 months. This study aimed to investigate the seroprevalence of antibodies to pertussis toxin among healthy people across all ages to determine the level of whole-cell vaccine-induced immunity in the population, and to identify which age group should be targeted for a booster dose. The lowest seronegative rate and highest geometric mean concentrations were found in the 0-10 years age group, corresponding to their recent pertussis vaccination. The proportion of people with undetectable IgG level was prominent, starting after 11 years of age onwards. Now that a reduced-dose pertussis vaccine with fewer adverse effects is available, a booster dose during adolescence should be considered in order to reduce the incidence of pertussis disease. Further studies exploring how long the reduced-dose pertussis vaccine can provide protective immunity against pertussis disease when administered to adults and adolescents should also be performed.
authors.affiliation: Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Pathumwan, Bangkok, 10330, Thailand.
authors.forename: Nasamon
authors.initials: N
authors.lastname: Wanlapakorn
authors.affiliation: Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Pathumwan, Bangkok, 10330, Thailand.
authors.forename: Varisara
authors.initials: V
authors.lastname: Ngaovithunvong
authors.affiliation: Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Pathumwan, Bangkok, 10330, Thailand.
authors.forename: Thanunrat
authors.initials: T
authors.lastname: Thongmee
authors.affiliation: Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Pathumwan, Bangkok, 10330, Thailand.
authors.forename: Preeyaporn
authors.initials: P
authors.lastname: Vichaiwattana
authors.affiliation: Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Pathumwan, Bangkok, 10330, Thailand.
authors.forename: Sompong
authors.initials: S
authors.lastname: Vongpunsawad
authors.affiliation: Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Pathumwan, Bangkok, 10330, Thailand.
authors.forename: Yong
authors.initials: Y
authors.lastname: Poovorawan
mesh_terms: D000293:Adolescent; D000328:Adult; D000907:Antibodies, Bacterial / Q000097:blood / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000276:immunology; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood / Q000276:immunology; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008875:Middle Aged; D037342:Pertussis Toxin / Q000276:immunology*; D010567:Pertussis Vaccine / Q000276:immunology*; D016036:Seroepidemiologic Studies; D013785:Thailand / Q000453:epidemiology; D014611:Vaccination; D014917:Whooping Cough / Q000453:epidemiology* / Q000517:prevention & control*; D055815:Young Adult
chemical_list: D000907:Antibodies, Bacterial; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D007074:Immunoglobulin G; D010567:Pertussis Vaccine; D037342:Pertussis Toxin
references.citation: Adv Neonatal Care. 2013 Apr;13(2):103-7
references.pmid: 23532029
references.citation: J Infect Dis. 1996 Nov;174 Suppl 3:S259-63
references.pmid: 8896526
references.citation: Pediatrics. 2015 Feb;135(2):331-43
references.pmid: 25560446
references.citation: Southeast Asian J Trop Med Public Health. 2014 Sep;45(5):1132-41
references.pmid: 25417516
references.citation: East Mediterr Health J. 2014 Oct 20;20(10):623-6
references.pmid: 25356693
references.citation: J Infect. 2011 Dec;63(6):441-6
references.pmid: 21864569
references.citation: PLoS One. 2010 Dec 01;5(12):e14183
references.pmid: 21152071
references.citation: Proc Natl Acad Sci U S A. 2015 Feb 3;112(5):E472-7
references.pmid: 25605878
references.citation: PLoS Med. 2010 Jun 22;7(6):e1000291
references.pmid: 20585374
references.citation: Vaccine. 2010 Apr 26;28(19):3285-90
references.pmid: 20226250
references.citation: J Infect Dis. 2001 Oct 15;184(8):1035-40
references.pmid: 11574919
references.citation: BMC Infect Dis. 2014 Jul 17;14:397
references.pmid: 25037057
references.citation: J Coll Physicians Surg Pak. 2012 Oct;22(10):677-8
references.pmid: 23058160
references.citation: APMIS. 2009 Dec;117(12):912-22
references.pmid: 20078557
references.citation: Eur J Pediatr. 2002 Mar;161(3):142-6
references.pmid: 11998910
references.citation: Epidemiol Infect. 2014 Apr;142(4):729-37
references.pmid: 24103353